Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma.
about
Trial watch: IDO inhibitors in cancer therapyResearch progress of indoleamine 2,3-dioxygenase inhibitorsThe IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cellsIDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer CellsThe indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cellsNon-hematopoietic expression of IDO is integrally required for inflammatory tumor promotionDecreased expression of transcription elongation factor A-like 7 is associated with gastric adenocarcinoma prognosis.Indoleamine 2,3-dioxygenase expression and activity in patients with hepatitis C virus-induced liver cirrhosis.Amino acid catabolism: a pivotal regulator of innate and adaptive immunity.Kynurenine and uric acid levels in chronic myeloid leukemia patients.Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.The Role of Indoleamine 2,3-Dioxygenase in Diethylnitrosamine-Induced Liver Carcinogenesis.Altered tryptophan metabolism as a paradigm for good and bad aspects of immune privilege in chronic inflammatory diseases.The potential role of indoleamine 2,3 dioxygenase (IDO) as a predictive and therapeutic target for diabetes treatment: a mythical truth.Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer.Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilegeImmune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccinesThe paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer.Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy.PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma.Expression and Prognostic Value of Indoleamine 2,3-dioxygenase in Pancreatic Cancer.Indoleamine 2,3-dioxygenase: As a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma.The immunoregulatory mechanisms of carcinoma for its survival and developmentTumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance.The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.Strong Correlation of Indoleamine 2,3-Dioxygenase 1 Expression with Basal-Like Phenotype and Increased Lymphocytic Infiltration in Triple-Negative Breast Cancer.Immunological landscape and immunotherapy of hepatocellular carcinoma.IDO-Mediated Tryptophan Degradation in the Pathogenesis of Malignant Tumor DiseaseMajor developments in the design of inhibitors along the kynurenine pathway.Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma.The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy.Inhibition of indoleamine 2,3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice.A novel immunohistochemical score to predict early mortality in acute myeloid leukemia patients based on indoleamine 2,3 dioxygenase expression.High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma.The significance of intertumor and intratumor heterogeneity in liver cancer.IDO1 in cancer: a Gemini of immune checkpoints.Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences.Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B.LW106, A Novel Inhibitor of IDO1, Suppresses Tumor Progression by Limiting Stroma-Immune Crosstalk and Cancer Stem Cell Enrichment in the Tumor Microenvironment.Tumor-Associated Fibroblasts and Microvessels Contribute to the Expression of Immunosuppressive Factor Indoleamine 2, 3-Dioxygenase in Human Esophageal Cancers.
P2860
Q27006866-536271F2-3B53-4B7C-A64A-6F4527BBE69BQ28257093-D143CB0F-F8CA-42CF-BE2F-CEC99383C53DQ28275608-D7B139BC-4E77-4ED2-8FB2-A53CEE97E5DFQ28551043-13B7E429-8E91-4638-8F55-809EC79006D5Q28744405-27BCDF15-F912-4339-B6DE-BE42C766A4F6Q34393455-B84D14A2-9C83-4879-B166-048F0F37952BQ34571259-5EBF46D0-528B-404C-8896-E698AC043D91Q35048483-B3876375-C481-4819-AB73-FED123C5E955Q35261125-CB7B75AC-21AD-49CC-BB5E-CE6811B1E283Q35507380-FC89F9ED-7B9D-4A8A-B41B-CFD29B27FD33Q35799094-050CBE2F-71F0-4548-9050-94C65C2E1DE3Q35884237-B09AB510-35F3-4A0C-9774-6934AB9A25A7Q35952614-1484B185-1A09-4F98-A919-6E5A4D45AF69Q36117580-FABF2ABE-1562-49C4-AB39-C8275546D505Q36866163-AA82F965-037B-4750-A433-8DC44324266DQ36899012-71AEE88B-AF45-4BD9-A16B-DC3CA7726E23Q37137360-06F6E349-AF48-41CE-93E9-FA5B5F74039FQ37329058-57D9DD8E-116F-43E1-8EF9-F82C1B43A7E6Q37352554-60BB9F0F-7302-4BEC-98CB-A80B6B3DBF33Q37705021-2F3CC6DE-C4E5-4599-BFBB-408A9DFCC861Q37711667-F7344A3B-E217-4D94-8DF0-19D608A1BF46Q37742979-2C97DEBB-6D42-4982-AC48-B66360656B72Q37831426-0D02E5A7-B315-47E6-BD8D-596697D1AF13Q37836612-D7919FE0-4869-4689-9ED0-690B9A2F9163Q38356502-CAC20EE1-BF54-44CC-97CE-92A9F1509B0EQ38406396-A8C93CBB-9053-4F87-A968-78C4D892E263Q38611895-6B33E563-30B2-4726-85C3-757FAC817ED9Q38728766-FE0206DF-D928-4B0F-AE03-134B471311B6Q38808400-93766D3B-FB21-4C7C-84FB-3217ECB0D4DDQ39514618-E79D8DA8-BCB5-4EB0-A004-9A3BE41F3758Q41149149-6A0DADA5-F960-402B-B3E3-C01106A2530FQ42089828-D868C00B-6470-474B-A1F4-61A26EC4ED82Q42379001-D004F173-81D3-4966-8B48-74EC1975DE5BQ42484093-C06788D2-B0F3-499C-843C-368FDF36AD28Q47750195-1DAA1072-C003-428D-8E2E-8DB31E9DA2ABQ47836812-575E1AC7-9FF9-4A01-AD97-E27B66C9BAE4Q48306002-F6D3F4C0-0DF3-4F9E-ADB6-CE27A19403A0Q51502194-15C11B04-8973-4511-AD80-A382AE5879ACQ52714204-9E07861F-C71F-4594-8441-72AD3ECC60E7Q52873461-4CF663BF-6344-4AA5-AB89-37768CB596D0
P2860
Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma.
@en
Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma.
@nl
type
label
Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma.
@en
Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma.
@nl
prefLabel
Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma.
@en
Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma.
@nl
P2093
P1476
Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma.
@en
P2093
De-sheng Weng
Hai-feng Song
Hua-kun Zhang
Jian-chuan Xia
Jian-jun Li
Min-shan Chen
P2888
P304
P356
10.1007/S00432-008-0395-1
P577
2008-04-26T00:00:00Z